# Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

> **NCT04730544** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 96 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- MSI-H Colorectal Cancer

## Interventions

- **DRUG:** Nivolumab 480mg + Ipilimumab
- **DRUG:** Nivolumab 240 mg + Ipilimumab

## Key facts

- **NCT ID:** NCT04730544
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-21
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730544, "Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04730544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*